Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome

Journal of Perinatology

Volumn 31, Issue 9, 2011, Pages 615-620

  Klinger, G ^a,b,c   Frankenthal, D ^c   Merlob, P ^a,b,c   Diamond, G ^a,c   Sirota, L ^a,c   Levinson Castiel, R ^a,c   Linder, N ^b,c   Stahl, B ^b   Inbar, D ^a,c  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

long term outcome; neonatal abstinence syndrome; selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGE; ANXIETY; ARTICLE; BAYLEY SCALE OF INFANT DEVELOPMENT II; BAYLEY SCALE OF INFANT DEVELOPMENT II TEST; BIRTH LENGTH; BIRTH WEIGHT; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; CLINICAL ARTICLE; COGNITION; CONNORS TEST; CONTROLLED STUDY; DENVER DEVELOPMENTAL SCREENING TEST II; FEMALE; FINNEGAN SCORE; HAMILTON ANXIETY SCALE; HEAD CIRCUMFERENCE; HUMAN; INTELLIGENCE TEST; LANGUAGE DISABILITY; LONGITUDINAL STUDY; MALE; MATERNAL AGE; MATERNAL ANXIETY; MOTOR PERFORMANCE; MUSCLE HYPOTONIA; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCORING SYSTEM; SEX RATIO; SOCIOPATHY; STANFORD BINET INTELLIGENCE SCALE TEST; WECHSLER INTELLIGENCE SCALE; WITHDRAWAL SYNDROME;

ADULT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MENTAL DISORDERS; NEONATAL ABSTINENCE SYNDROME; NEUROPSYCHOLOGICAL TESTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 80052386238     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2010.211     Document Type: Article

References (32)

1. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy. Effects on the infant. Drug Safety 2005; 28(7): 565-581. (Pubitemid 41003046)
2. Koren G, Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation. Can J Clin Pharmacol 2009; 16(1): e66-e67.
3. Bakker MK, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65(4): 600-606. (Pubitemid 351365128)
4. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009; 23(6): 493-509.
5. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196(6): 544.e1-5.
6. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psych Relat Sci 2008; 45(2): 107-113.
7. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65: 230-237.
8. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome following in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160: 173-176. (Pubitemid 43213863)
9. Isbister GK, Dawson A, Whyte IM, Prior FH, Clancy C, Smith AJ. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001; 85: F147-F148. (Pubitemid 32816629)
10. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehaviour. Pediatrics 2004; 113(2): 368-375. (Pubitemid 38177090)
11. Borue X, Chen J, Condron BG. Developmental effects of SSRIsFlessons learned from animal studies. Int J Dev Neurosci 2007; 25(6): 341-347. (Pubitemid 350051324)
12. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviours in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161(1): 22-29. (Pubitemid 46045459)
13. Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005; 115: 411-425. (Pubitemid 43193826)
14. Nulman I, Rovet J, Stewart DE et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-262. (Pubitemid 27044627)
15. Casper RC, Fleisher BE, Lee-Ancajas JC et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402-408. (Pubitemid 36521227)
16. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau R et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006; 163: 1026-1032. (Pubitemid 44464489)
17. Finnegan LP. Neonatal abstinence syndrome In: Nelson N (ed). Current Therapy in Neonatal Perinatal Medicine. BC Decker: Toronto, 1990, pp 314-320.
18. Nellhaus G. Head circumference from birth to eighteen years. Practical composite international and interracial graphs. Pediatrics 1968; 41(1): 106-114.
19. Frankenburg WK, Camp BW, Van Natta PA, Demersseman JA. Reliability and stability of the Denver Developmental Screening Test. Child Dev 1971; 42: 1315-1325.
20. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 1988; 14(1): 61-68. (Pubitemid 18016383)
21. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159(11): 1889-1895. (Pubitemid 35283255)
22. Kaitz M, Maytal HR, Devor N, Bergman L, Mankuta D. Maternal anxiety, mother-infant interactions, and infants' response to challenge. Infant Behav Dev 2010; 33(2): 136-148.
23. Feldman R, Granat A, Pariente C, Kanety H, Kuint J, Gilboa-Schechtman E. Maternal depression and anxiety across the postpartum year and infant social engagement, fear regulation, and stress reactivity. J Am Acad Chil Adolesc Psychiatry 2009; 48(9): 919-927.
24. Min W, Li T, Ma X, Li Z, Yu T, Gao D et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 2009; 205(3): 409-417.
25. Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy 2009; 29(7): 822-831.
26. Hilli J, Heikkinen T, Rontu R, Lehtimä ki T, Kishida I, Aklillu E et al. MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol 2009; 19(5): 363-370.
27. Kronenberg S, Frisch A, Rotberg B, Carmel M, Apter A, Weizman A. Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics 2008; 9(11): 1725-1736.
28. Henrichs J, Schenk JJ, Roza SJ, van den Berg MP, Schmidt HG, Steegers EA et al. Maternal psychological distress and fetal growth trajectories: the Generation R Study. Psychol Med 2010; 40(4): 633-643.
29. Hosseini SM, Biglan MW, Larkby C, Brooks MM, Gorin MB, Day NL. Trait anxiety in pregnant women predicts offspring birth outcomes. Paediatr Perinat Epidemiol 2009; 23(6): 557-566.
30. Marcus SM. Depression during pregnancy: rates, risks and consequencesFMotherisk Update 2008. Can J Clin Pharmacol 2009; 16(1): e15-e22.
31. Davidson S, Prokonov D, Taler M, Maayan R, Harell D, Dil-Adi I et al. Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res 2009; 65(2): 236-241.
32. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163(10): 949-954.